Sherise Rogers, MD, MPH

Assistant Professor

Department: MD-HEMATOLOGY/ONCOLOGY

Business Phone: (352) 273-7832

Business Email: sherise.rogers@medicine.ufl.edu

About Sherise Rogers

Sherise C. Rogers, M.D., M.P.H., received her bachelor’s degree from Cornell University in 2009 in Human Development with a minor in Biological Sciences. She then obtained her Medical Doctorate in 2014 and Master in Public Health in 2015 from New York Medical College.

Dr. Rogers completed her Internal Medicine Residency at Stony Brook University Medical Center in New York in 2017. She completed her Hematology & Oncology Fellowship at The Ohio State University Medical Center where she also served as Wellness Chief Fellow in 2020. Aside from her educational achievements, Dr. Rogers has a passion for mentoring and has completed many professional development programs such as the Physician Leadership Academy and Medical Journalism elective at the ABC News Medical Unit in New York City.

Her peer reviewed publications and presentations have concentrations in gastrointestinal oncology, diversity and inclusion, physician wellness and strategies to address burnout among hematology and oncology trainees. She is a member of many professional memberships such as the ASCO and AACR.

Dr. Rogers’ area of clinical and research focus are gastrointestinal malignancies with a special interest in pancreatic cancer, the microbiome, circulating tumor DNA and cancer disparities.

Teaching Profile

Courses Taught

2021-2022

BMS6816 Cancer Bio Clin Oncol

Clinical Profile

Specialties

Cancer
Hematology and Oncology

Areas of Interest

Colorectal cancer
Esophageal cancer
Gastrointestinal cancer
Liver cancer – hepatocellular carcinoma
Pancreatic cancer
Stomach cancer

Research Profile

Areas of Interest

Hematology and Oncology

Publications

2023

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.

Future oncology (London, England). 19(27):1841-1851 [DOI] 10.2217/fon-2023-0256. [PMID] 37753702.

PubMed · Publisher’s Site

2023

Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.

BMJ case reports. 16(12) [DOI] 10.1136/bcr-2023-255916. [PMID] 38142057.

PubMed · Publisher’s Site

2023

Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis.

Journal of hepatocellular carcinoma. 10:1129-1141 [DOI] 10.2147/JHC.S417273. [PMID] 37489126.

PubMed · Publisher’s Site

2023

Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes.

Cancer control : journal of the Moffitt Cancer Center. 30 [DOI] 10.1177/10732748231197878. [PMID] 37703814.

1 citation · PubMed · Publisher’s Site

2023

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study.

Cancers. 15(20) [DOI] 10.3390/cancers15205055. [PMID] 37894422.

1 citation · PubMed · Publisher’s Site

2023

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.

Journal of the National Medical Association. 115(2):164-174 [DOI] 10.1016/j.jnma.2023.01.008. [PMID] 36801148.

1 citation · PubMed · Publisher’s Site

2023

Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 32(12):1675-1682 [DOI] 10.1158/1055-9965.EPI-23-0251. [PMID] 37788369.

PubMed · Publisher’s Site

2022

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.

Future oncology (London, England). [DOI] 10.2217/fon-2022-0392. [PMID] 36399037.

PubMed · Publisher’s Site

2022

Chemotherapy is associated with improved survival in a national cohort of stage IV pancreatic adenosquamous carcinoma.

Journal of gastrointestinal oncology. 13(6):3207-3215 [DOI] 10.21037/jgo-22-434. [PMID] 36636088.

PubMed · Publisher’s Site

2021

Immunotherapy Management in Special Cancer Patient Populations.

JCO oncology practice. 17(5):240-245 [DOI] 10.1200/OP.20.00996. [PMID] 33710933.

7 citations · PubMed · Publisher’s Site

2017

The First Case of HER2+ Invasive Ductal Carcinoma Arising From a Breast Hamartoma and Literature Review.

Journal of the National Medical Association. 109(1):55-59 [DOI] 10.1016/j.jnma.2016.10.002. [PMID] 28259217.

2 citations · PubMed · Publisher’s Site

Grants

Jan 2024 ACTIVE

Winn CILA

Role: Principal Investigator

Funding: Conquer Cancer Foundation of the ASCO

Sep 2023 ACTIVE

2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center

Role: Other

Funding: NATL INST OF HLTH NCI

Oct 2021 – Jan 2024

Intestinal Microbiota Associations with Toxicity and Outcomes in Patients with Pancreatic Cancer during Neoadjuvant Curative Treatment

Role: Principal Investigator

Funding: BRISTOL-MYERS SQUIBB FOUNDATION

Jun 2020 ACTIVE

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Na?ve Metastatic Pancreatic Cancer (GIANT)

Role: Principal Investigator

Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

Jul 2019 – Jun 2022

UF Health Cancer Center Pilot Projects funded by UF Foundation Allocated Funds

Role: Project Manager

Funding: UF FOUNDATION

Sep 2018 – Aug 2023

2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center

Role: Other

Funding: NATL INST OF HLTH NCI